Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Although the science related to variation in responses to medication has been developing for decades, the importance and
practical application has not translated into clinical practice. The first step in improving outcomes related to individual
medication response variation based on gender, and race, is in the examination of evidence that can result in strategies to provide
effect medical care. For end of life care to be equitable, culturally congruent, and overall competent, this aspect of patient care
demands consideration and illumination. Inter-individual variation in drug response poses a serious problem in the management
of patients who are receiving medications to treat or prevent any disease or illness, or to provide comfort during end of life. Due to
individual variations in response to drug therapy, this variability can result in toxicity and adverse drug reactions (ADRs). Major
factors that account for differences in drug response include cultural practices, race (genetic composition), and gender. These
factors merit consideration when determining which medication and dosage will provide appropriate treatment, or pain relief.
Persons who are prescribing, administering, or taking medications can make the best decisions with regard to the most effective
medication regimen, when they understand fundamental aspects of inter-individual variations and disparities in drug responses.
One specific factor genetic factor that accounts for the variation in drug response is Cytochrome p450. Although knowledge
about the impact of Cytochrome p450 on individual variations in drug response has been known for decades, the transition to
clinical practice has not evolved. It is estimated that 90% of current prescribed medications are mediated by these enzymes that
result in variations based on the individual�s phenotype. When considering cultural practices and racial differences, in many
cases we are under medicating, overmedicating or using the wrong medication to achieve a specific outcome. For example, the
mortality rate among African American women in the United States with breast cancer is unacceptable. This is in part due to the
fact that clinical drug trials are done with primarily Caucasian females. Drug guidelines and doses established based on these data
involving a predominant group. When medications that are effective in one racial group are given for same illnesses in another
racial group, the medications can be not only ineffective, but detrimental. For competent and equitable palliative care, health care
professionals have a responsibility to enhance knowledge of scientific data that supports variation based on race and gender. Only
through recognizing the value of the evidence and it implications, can transcultural nursing related to medication prescription and
administration truly be competent, skilled, and effective.